*Optimal dilutions/concentrations should be determined by the researcher.
Not tested in other applications.
Myc-DDK-tagged VHL-transfected 293T
Bovine, Dog(>80% identity)
1XPBS, 20% Glycerol (pH7). 0.025% ProClin 300 was added as a preservative.
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
0.93mg/ml(Please refer to the vial label for the specific concentration.)
Recombinant protein encompassing a sequence within the center region of human VHL. The exact sequence is proprietary.
Purified by antigen-affinity chromatography.
For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
HRCA1 antibody, RCA1 antibody, VHL1 antibody, VHL antibody, pVHL antibody, elongin binding protein antibody, protein G7 antibody, von Hippel-Lindau disease tumor suppressor antibody, von Hippel-Lindau tumor suppressor antibody
Isoform 1: Cytoplasm , Membrane; Peripheral membrane protein , Nucleus , Isoform 3: Cytoplasm
Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed. [provided by RefSeq]